Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review

Tsiropoulos, Georgios N.; Seliniotaki, Aikaterini K; Haidich, Anna‐Bettina; Ziakas, Nikolaos; Mataftsi, Asimina

doi:10.1007/s10792-022-02480-6

Cited by 12 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Retinal tissue ablation, visual eld reduction, and myopia occurrence are lower than laser photocoagulation. (5,14,(34)(35)(36) In our study, the incidence of severe ROP was 3.58 %. 19 patients received IVB injections and retinal vascularization was completed in all of them.…”

Section: Discussionmentioning

confidence: 74%

Incidence and Risk Factors of Retinopathy of Prematurity in Southeast Iran: A Retrospective Cohort Study

Maleki,

Sargazi,

Yousefian

et al. 2024

Preprint

View full text Add to dashboard Cite

Background and objectives: Retinopathy of prematurity (ROP) is a significant cause of preventable premature infant vision loss. Many studies have reported different risk factors depending on the region. In this study, we evaluated the incidence of ROP and associated risk factors in a referral eye hospital in southeast Iran. Methods This was a retrospective cohort study of preterm infants with birth weight (BW) ≤ 2000 grams or gestational age (GA) ≤ 34weeks and infants with 34 < GA < 37weeks or GA < 37weeks and BW > 2000 grams referred by their pediatricians to our center from March 2022 until March 2023. Results 920 infants met the inclusion criteria for the study, the incidence of ROP and severe ROP was 20.2% and 3.58% respectively. Results of logistic regression analysis showed higher GA and BW as protective factors against ROP occurrence. History of blood transfusion and phototherapy increased ROP development. Conclusion Lower GA, lower BW, history of blood transfusion, and phototherapy were associated with ROP development. Phototherapy decreased the need for treatment among ROP patients.

show abstract

Section: Discussionmentioning

confidence: 74%

Incidence and Risk Factors of Retinopathy of Prematurity in Southeast Iran: A Retrospective Cohort Study

Maleki,

Sargazi,

Yousefian

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Laser treatment may be more efficacious in managing ROP with a significantly lower retreatment incidence than anti-VEGF treatment, and supplemental laser ablative treatment could reduce recurrence after initial anti-VEGF treatment [12,15]. However, myopia decreased significantly more with anti-VEGF treatment than with laser treatment [12,14].…”

Section: Discussionmentioning

confidence: 99%

“…However, combined systematic reviews and meta-analyses, meta-analyses, or reviews [3,4,[10][11][12][13][14][15] comparing the laser-treated eyes with anti-VEGF monotherapy revealed that anti-VEGF injection caused less myopia, a lower prevalence of high myopia or astigmatism, and an overall lower risk of refractive errors in childhood. A subgroup analysis revealed a higher degree of myopia in aggressive posterior ROP than in type 1 ROP [11].…”

Section: Introductionmentioning

confidence: 99%

Refractive outcomes in infants treated for retinopathy of prematurity

Heidary¹,

Gharebaghi²

2022

Med Hypothesis Discov Innov Optom

View full text Add to dashboard Cite

Background: Infants treated for retinopathy of prematurity (ROP) can develop visually significant refractive error. However, the degree of refractive error may differ between laser treatment and intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection. We reviewed studies that investigated refractive error outcomes of treatment in premature infants with ROP. Methods: In this narrative review, a literature search was carried out in PubMed/MEDLINE from 01/01/2000 to 20/10/2022 without language restrictions, using the following keywords: “anti-VEGF,” “ROP” or “prematurity retinopathy,” and “laser.” We included comparative studies on refractive error outcomes of intravitreal anti-VEGF and laser treatments, a combination of both modalities simultaneously or sequentially, and two anti-VEGF agents. Results: The initial search yielded 164 records. We reviewed the titles and abstracts of the retrieved papers and the reference list of published systematic reviews and meta-analyses, meta-analyses, or reviews on our topic. Thirty-three records fulfilled our inclusion criteria, which included refractive outcomes in 4350 eyes of 2359 participants treated for ROP. Based on the reported refractive outcomes, we divided the studies into four categories: 1) those that revealed a higher rate of refractive error in the laser-treated eyes than in the anti-VEGF-treated eyes; 2) those that revealed no significant difference in refractive outcomes between the two treatment modalities; 3) those that revealed a higher rate of refractive error in the anti-VEGF-treated eyes or compared refractive outcomes between two anti-VEGF agents; and 4) those that reported refractive outcomes in the eyes that received combined simultaneous or sequential treatment with laser after initial anti-VEGF treatment. We also summarized the refractive outcomes of all included primary studies in each category. Conclusions: This study showed that the laser-treated eyes experienced more myopic shift. However, the refractive outcomes in premature infants of laser treatment, anti-VEGF treatment, and a combination of both modalities simultaneously or sequentially were often contradictory. This variability resulted from obvious differences in the sample size, different follow-up durations, or inhomogeneous study or treatment designs. Further well-designed prospective trials on refractive outcomes and the trend of changes in the refractive status over long-term follow-ups in the eyes treated with ROP are necessary to identify consensus results concerning real-world refractive outcomes of each treatment modality or simultaneous or sequential combination of both modalities, to suggest a safe and effective treatment option for eye care professionals.

show abstract

“…One systematic review published in 2022 concluded that more information is required concerning the adverse events, complications, and unfavourable functional and structural outcomes of the two treatment modalities in the long term. 12 In the interim analysis at 2 years of 180 infants in the RAINBOW trial, 13 as among 109 children at 2.5 years in the BEAT-ROP trial, 14 there was significant reduction of high myopia following anti-VEGF treatment compared to laser, but no visual acuity data have been published following a trial of anti-VEGF therapy for ROP.…”

Section: Introductionmentioning

confidence: 99%

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial

Marlow,

Reynolds,

Lepore

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review

Cited by 12 publications

References 60 publications

Incidence and Risk Factors of Retinopathy of Prematurity in Southeast Iran: A Retrospective Cohort Study

Incidence and Risk Factors of Retinopathy of Prematurity in Southeast Iran: A Retrospective Cohort Study

Refractive outcomes in infants treated for retinopathy of prematurity

Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): five-year outcomes of a randomised trial

Contact Info

Product

Resources

About